Citadel Advisors’s UroGen Pharma URGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.82M Sell
267,996
-469,761
-64% -$9.42M ﹤0.01% 4400
2025
Q4
$17.3M Buy
737,757
+135,480
+22% +$2.94M 0.01% 2532
2025
Q3
$12M Buy
602,277
+59,081
+11% +$1.06M 0.01% 2993
2025
Q2
$7.44M Buy
543,196
+353,519
+186% +$3.39M 0.01% 3458
2025
Q1
$2.1M Sell
189,677
-39,108
-17% -$417K ﹤0.01% 5451
2024
Q4
$2.44M Sell
228,785
-13,281
-5% -$159K ﹤0.01% 5223
2024
Q3
$3.07M Buy
242,066
+167,704
+226% +$2.49M ﹤0.01% 4735
2024
Q2
$1.25M Buy
74,362
+2,546
+4% +$36.2K ﹤0.01% 6170
2024
Q1
$1.08M Sell
71,816
-72,063
-50% -$1.18M ﹤0.01% 6767
2023
Q4
$2.16M Buy
143,879
+136,883
+1,957% +$1.78M ﹤0.01% 5217
2023
Q3
$98K Sell
6,996
-40,984
-85% -$658K ﹤0.01% 10924
2023
Q2
$497K Sell
47,980
-29,196
-38% -$322K ﹤0.01% 7958
2023
Q1
$713K Buy
77,176
+28,239
+58% +$260K ﹤0.01% 7518
2022
Q4
$434K Buy
48,937
+35,216
+257% +$334K ﹤0.01% 8544
2022
Q3
$114K Buy
+13,721
New +$114K ﹤0.01% 10983
2021
Q4
Sell
-57,298
Closed -$964K 14944
2021
Q3
$964K Sell
57,298
-11,251
-16% -$178K ﹤0.01% 8253
2021
Q2
$1.05M Buy
68,549
+30,604
+81% +$553K ﹤0.01% 8249
2021
Q1
$739K Buy
37,945
+1,619
+4% +$34.4K ﹤0.01% 8829
2020
Q4
$655K Buy
36,326
+11,367
+46% +$238K ﹤0.01% 7636
2020
Q3
$481K Buy
24,959
+3,966
+19% +$89.8K ﹤0.01% 7371
2020
Q2
$548K Sell
20,993
-47,285
-69% -$1.16M ﹤0.01% 6917
2020
Q1
$1.22M Sell
68,278
-5,405
-7% -$146K ﹤0.01% 4974
2019
Q4
$2.46M Sell
73,683
-21,128
-22% -$577K ﹤0.01% 4082
2019
Q3
$2.26M Sell
94,811
-6,994
-7% -$229K ﹤0.01% 4285
2019
Q2
$3.66M Sell
101,805
-67,844
-40% -$2.5M ﹤0.01% 3548
2019
Q1
$6.27M Sell
169,649
-204,683
-55% -$8.58M 0.01% 2673
2018
Q4
$16.1M Buy
374,332
+98
+0% +$4.41K 0.02% 1409
2018
Q3
$17.7M Buy
374,234
+53,200
+17% +$2.47M 0.02% 1507
2018
Q2
$16M Buy
321,034
+239,676
+295% +$13.9M 0.02% 1506
2018
Q1
$4.04M Buy
+81,358
New +$4.08M 0.01% 2699

Other funds holding URGN